NCNA

Nucana Plc (NCNA) - Form 20-F Summary

Business Context and Reporting Period

Company: Nucana Plc
Reporting Period: Fiscal Year Ended December 31, 2024
Filing Date: March 20, 2025
Business Overview: Nucana is a clinical-stage biopharmaceutical company developing "ProTides," a proprietary technology platform designed to transform nucleoside analogs into more effective and safer cancer medicines. The company has no approved products and generates no revenue. Its primary focus is on two lead candidates: NUC-7738 (Phase 2) and NUC-3373 (Phase 1b/2).

Key Financial Metrics (Year Ended Dec 31, 2024)

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by approximately £9.9 million year-over-year. R&D expenses fell by £7.1 million, driven by reduced clinical trial spending on NuTide:302 and NuTide:701, and lower patent defense costs. Administrative expenses decreased by £1.1 million due to lower personnel and share-based payment costs.
• Cash Position: Cash and cash equivalents declined by £10.5 million to £6.7 million, reflecting a net cash outflow from operations of £19.1 million, partially offset by £8.2 million in financing proceeds from an "at-the-market" (ATM) equity offering.
• Foreign Exchange: The company reported a net foreign exchange gain of £0.2 million in 2024, compared to a loss of £1.2 million in 2023, primarily due to the appreciation of the U.S. dollar against the pound sterling.
• Share Capital: The company issued 89 million ordinary shares via its ATM program in 2024, raising gross proceeds of £8.7 million.

Guidance, Outlook, and Risks

Going Concern Warning: The company has identified conditions that raise substantial doubt about its ability to continue as a going concern. Management states that current cash reserves (£6.7 million) are insufficient to fund anticipated operations for the next 12 months. The company plans to commence an equity financing process but notes that its ADSs are currently trading below the nominal value of ordinary shares (£0.04), necessitating a proposed share sub-division to facilitate fundraising.

Clinical Outlook:

• NUC-7738: Phase 2 data presented in September 2024 showed encouraging disease control in melanoma patients. The company expects to initiate an expansion of this trial in 2025 and seek FDA regulatory guidance.
• NUC-3373: Phase 1b/2 data presented in November 2024 showed tumor volume reductions in solid tumors. The company expects to announce further data in 2025.
• Acelarin: The Phase 3 trial (NuTide:121) was discontinued in March 2022 due to futility analysis. Future development options are being assessed.

Key Risks:

• Liquidity: Failure to secure additional financing could force a wind-down of operations or bankruptcy.
• Regulatory Approval: No assurance that product candidates will receive regulatory approval or achieve commercial success.
• Intellectual Property: Ongoing patent disputes and the risk of third-party challenges to the ProTide platform.
• Market Volatility: ADS trading price volatility and potential delisting risks if minimum bid price requirements are not met.

Investor Verification Checklist

• Financing Status: Verify the outcome of the proposed general meeting (scheduled for April 7, 2025) regarding the share sub-division and the success of the subsequent equity financing process.
• Cash Runway: Monitor quarterly cash burn rates and the sufficiency of current cash balances relative to the 12-month going concern period.
• Clinical Milestones: Track the initiation of the NUC-7738 trial expansion and the release of full data from the NUC-3373 NuTide:303 trial in 2025.
• Share Price vs. Nominal Value: Confirm the trading price of ADSs relative to the nominal share value to assess the feasibility of future capital raises without further corporate actions.
• Patent Litigation: Review updates on intellectual property disputes, particularly regarding the ProTide platform and potential challenges from third parties.